SELECT MDS-1

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)

Near Add Your Location

Sorting 20 by

Center of Excellence

University of Arizona Cancer Center
Tucson, AZ
  • Accepting patients

Center of Excellence

USC Norris Comprehensive Cancer Center - Keck School of Medicine
University of Southern California
Los Angeles, CA
  • Accepting patients

Center of Excellence

UCLA Jonsson Comprehensive Cancer Center
University of California Los Angeles
Los Angeles, CA
  • Accepting patients
Comprehensive Hematology and Oncology
Saint Petersburg, FL
  • Accepting patients

Center of Excellence

Holden Comprehensive Cancer Center - University of Iowa
University of Iowa Hospitals and Clinics
Iowa City, IA
  • Accepting patients
Tulane Cancer Center
Tulane University School of Medicine
New Orleans, LA
  • Accepting patients

Center of Excellence

Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, MD
  • Accepting patients
504 hidden based on your filters. Show All

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.